Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer

Table 1 Patient, tumor and treatment characteristics

	n	%	N
	médiane	[min-max]	N
Center			91
CFB	16	17.6%
CLB	40	44%
ICL	28	30.8%
IGR	7	7.7%
Age	63.43	[42.39–87.34]	91
Gender			91
F	33	36.3%
M	58	63.7%
PS			90
0	39	43.3%
1	43	47.8%
2	8	8.9%
Smoker (current or former)	73	85.9%	85
Respiratory comorbidity	26	29.2%	89
Cardiovascular comorbidity	24	27.3%	88
Other cancer history	19	21.6%	88
Other significant comorbidity	21	23.9%	88
Histology			91
Adenocarcinoma	59	64.8%
Squamous cell	16	17.6%
Small Cell Lung Cancer	8	8.8%
Other	8	8.8%
Molecular alteration	18	19.8%	91
EGFR	8	9%
ALK	2	2.2%
KRAS	4	4.5%
HER2	2	2.3%
cMET amplification	1	1.1%
cMET mutation	1	1.1%
T			89
T1	18	20.2%
T2	35	39.3%
T3	25	28.1%
T4	11	12.4%
N			89
N0	31	34.8%
N1	16	18%
N2	26	29.2%
N3	14	15.7%
Nx	2	2.2%
Pre-therapeutic PET-TDM	79	87.8%	90
Metastase(s) operability			91
Yes	7	7.7%
No	41	45.1%
Not reported	43	47.3%
Controlled primitive lesion	77	84.6%	91
Number of metastase(s)			91
1	83	91.2%
> = 2	8	8.8%
Characteristics of metastatic evolution			91
Metachronous	63	69.2%
Synchronous	28	30.8%
Indication			91
Oligopersistance	18	19.8%
Oligometastatic	10	11%
Oligoprogression	18	19.8%
Oligorecurrence	45	49.5%
Treated site			99
Liver	12	12.1%
Lymph node	7	7.1%
Bone	20	20.2%
Lung	21	21.2%
Spine	12	12.1%
Adrenal	27	27.3%
Contralateral to primitive lesion	13	48.1%	27
Homolateral to primitive lesion	14	51.9%	27
Ongoing systemic treatment before irradiation			91
No	58	63.7%
Yes	33	36.3%
Systemic treatment interruption during irradiation			33
No	1	2.9%
Yes	32	97.1%

CFB Centre François Baclesse, CLB Centre Léon Bérard, ICL Institut de Cancérologie de Lorraine, IGR Institut Gustave Roussy

ISSN: 1471-2407